- Home
- LXEH vs RNXT Comparison
LXEH vs RNXT Comparison
Compare LXEH & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- RNXT
- Stock Information
- Founded
- LXEH 2001
- RNXT 2012
- Country
- LXEH China
- RNXT United States
- Employees
- LXEH N/A
- RNXT N/A
- Industry
- LXEH Other Consumer Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- RNXT Health Care
- Exchange
- LXEH Nasdaq
- RNXT Nasdaq
- Market Cap
- LXEH 55.2M
- RNXT 44.6M
- IPO Year
- LXEH 2020
- RNXT 2021
- Fundamental
- Price
- LXEH $1.76
- RNXT $1.14
- Analyst Decision
- LXEH
- RNXT Strong Buy
- Analyst Count
- LXEH 0
- RNXT 2
- Target Price
- LXEH N/A
- RNXT $7.25
- AVG Volume (30 Days)
- LXEH 474.8K
- RNXT 107.8K
- Earning Date
- LXEH 09-15-2025
- RNXT 08-14-2025
- Dividend Yield
- LXEH N/A
- RNXT N/A
- EPS Growth
- LXEH N/A
- RNXT N/A
- EPS
- LXEH N/A
- RNXT N/A
- Revenue
- LXEH $4,493,795.00
- RNXT $240,000.00
- Revenue This Year
- LXEH N/A
- RNXT $3,104.65
- Revenue Next Year
- LXEH N/A
- RNXT $301.89
- P/E Ratio
- LXEH N/A
- RNXT N/A
- Revenue Growth
- LXEH N/A
- RNXT N/A
- 52 Week Low
- LXEH $1.15
- RNXT $0.75
- 52 Week High
- LXEH $50.08
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- LXEH 49.04
- RNXT 33.69
- Support Level
- LXEH $1.81
- RNXT $1.23
- Resistance Level
- LXEH $2.50
- RNXT $1.28
- Average True Range (ATR)
- LXEH 0.39
- RNXT 0.06
- MACD
- LXEH 0.09
- RNXT -0.01
- Stochastic Oscillator
- LXEH 34.86
- RNXT 15.00
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.